LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $8,720 | -7.6% | 8,000 | 0.0% | 0.01% | -14.3% |
| Q3 2023 | $9,440 | -16.3% | 8,000 | 0.0% | 0.01% | -12.5% |
| Q2 2023 | $11,280 | +93900.0% | 8,000 | 0.0% | 0.01% | -11.1% |
| Q1 2023 | $12 | +33.3% | 8,000 | 0.0% | 0.01% | +28.6% |
| Q4 2022 | $9 | -99.9% | 8,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $9,000 | -30.8% | 8,000 | 0.0% | 0.01% | -30.0% |
| Q2 2022 | $13,000 | -35.0% | 8,000 | 0.0% | 0.01% | -23.1% |
| Q1 2022 | $20,000 | 0.0% | 8,000 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $20,000 | +53.8% | 8,000 | +61.0% | 0.01% | +44.4% |
| Q3 2021 | $13,000 | -7.1% | 4,970 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $14,000 | +16.7% | 4,970 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $12,000 | +33.3% | 4,970 | 0.0% | 0.01% | +50.0% |
| Q4 2020 | $9,000 | +125.0% | 4,970 | 0.0% | 0.01% | +50.0% |
| Q1 2020 | $4,000 | 0.0% | 4,970 | 0.0% | 0.00% | +33.3% |
| Q4 2019 | $4,000 | -20.0% | 4,970 | 0.0% | 0.00% | -25.0% |
| Q3 2019 | $5,000 | – | 4,970 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |